BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 26026587)

  • 1. The impact of immunohistochemical staining with ezrin-carbonic anhydrase IX and neuropilin-2 on prognosis in patients with metastatic renal cell cancer receiving tyrosine kinase inhibitors.
    Cetin B; Gonul II; Buyukberber S; Afsar B; Gumusay O; Algın E; Turan N; Ozet A; Benekli M; Coskun U
    Tumour Biol; 2015 Nov; 36(11):8471-8. PubMed ID: 26026587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors in patients with advanced renal cell carcinoma.
    Muriel López C; Esteban E; Berros JP; Pardo P; Astudillo A; Izquierdo M; Crespo G; Sanmamed M; Fonseca PJ; Martínez-Camblor P
    Clin Genitourin Cancer; 2012 Dec; 10(4):262-70. PubMed ID: 22959659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
    Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
    Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic tissue biomarker exploration for patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Park I; Cho YM; Lee JL; Ahn JH; Lee DH
    Tumour Biol; 2016 Apr; 37(4):4919-27. PubMed ID: 26526582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas.
    Driessen A; Landuyt W; Pastorekova S; Moons J; Goethals L; Haustermans K; Nafteux P; Penninckx F; Geboes K; Lerut T; Ectors N
    Ann Surg; 2006 Mar; 243(3):334-40. PubMed ID: 16495697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carbonic anhydrase IX is a prognostic biomarker in glioblastoma multiforme.
    Cetin B; Gonul II; Gumusay O; Bilgetekin I; Algin E; Ozet A; Uner A
    Neuropathology; 2018 Oct; 38(5):457-462. PubMed ID: 29952031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular biomarkers for advanced renal cell carcinoma: implications for prognosis and therapy.
    Kim HS; Kim WS; Park SH; Jung CW; Choi HY; Lee HM; Jeon SS; Ha H; Hwang IG; Lee S; Lim HY
    Urol Oncol; 2010; 28(2):157-63. PubMed ID: 18976937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.
    Bui MH; Seligson D; Han KR; Pantuck AJ; Dorey FJ; Huang Y; Horvath S; Leibovich BC; Chopra S; Liao SY; Stanbridge E; Lerman MI; Palotie A; Figlin RA; Belldegrun AS
    Clin Cancer Res; 2003 Feb; 9(2):802-11. PubMed ID: 12576453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.
    Seidel C; Busch J; Weikert S; Steffens S; Fenner M; Ganser A; Grünwald V
    Eur J Cancer; 2012 May; 48(7):1023-30. PubMed ID: 22436979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival.
    Hui EP; Chan AT; Pezzella F; Turley H; To KF; Poon TC; Zee B; Mo F; Teo PM; Huang DP; Gatter KC; Johnson PJ; Harris AL
    Clin Cancer Res; 2002 Aug; 8(8):2595-604. PubMed ID: 12171890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET).
    Choueiri TK; Cheng S; Qu AQ; Pastorek J; Atkins MB; Signoretti S
    Urol Oncol; 2013 Nov; 31(8):1788-93. PubMed ID: 23141780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble carbonic anhydrase IX is not an independent prognostic factor in human renal cell carcinoma.
    Papworth K; Sandlund J; Grankvist K; Ljungberg B; Rasmuson T
    Anticancer Res; 2010 Jul; 30(7):2953-7. PubMed ID: 20683038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma.
    Bui MH; Visapaa H; Seligson D; Kim H; Han KR; Huang Y; Horvath S; Stanbridge EJ; Palotie A; Figlin RA; Belldegrun AS
    J Urol; 2004 Jun; 171(6 Pt 1):2461-6. PubMed ID: 15126876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ezrin is a prognostic biomarker in patients with clear cell metastatic renal cell carcinoma receiving sunitinib.
    Cetin B; Gonul II; Gumusay O; Afsar B; Bilgetekin I; Ozet A; Uner A
    J Cancer Res Ther; 2021; 17(2):408-413. PubMed ID: 34121685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma.
    Sandlund J; Oosterwijk E; Grankvist K; Oosterwijk-Wakka J; Ljungberg B; Rasmuson T
    BJU Int; 2007 Sep; 100(3):556-60. PubMed ID: 17608827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer.
    Hussain SA; Ganesan R; Reynolds G; Gross L; Stevens A; Pastorek J; Murray PG; Perunovic B; Anwar MS; Billingham L; James ND; Spooner D; Poole CJ; Rea DW; Palmer DH
    Br J Cancer; 2007 Jan; 96(1):104-9. PubMed ID: 17213826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma.
    Klatte T; Seligson DB; Riggs SB; Leppert JT; Berkman MK; Kleid MD; Yu H; Kabbinavar FF; Pantuck AJ; Belldegrun AS
    Clin Cancer Res; 2007 Dec; 13(24):7388-93. PubMed ID: 18094421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels.
    Bache M; Reddemann R; Said HM; Holzhausen HJ; Taubert H; Becker A; Kuhnt T; Hänsgen G; Dunst J; Vordermark D
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1481-7. PubMed ID: 17056190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study.
    Liao SY; Darcy KM; Randall LM; Tian C; Monk BJ; Burger RA; Fruehauf JP; Peters WA; Stock RJ; Stanbridge EJ
    Gynecol Oncol; 2010 Mar; 116(3):452-8. PubMed ID: 19913895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.